Related Experiment Videos
Prevention and management of chronic heart failure in patients at risk
Livio Dei Cas1, Marco Metra, Savina Nodari
1Cattedra di Cardiologia, Università di Brescia, Brescia, Italy.
Insights
Preventing heart failure (HF) is crucial, with hypertension and diabetes as key risks. Medications like ACE inhibitors and beta-blockers show promise in preventing HF, especially in high-risk patients.
Area of Science:
- Cardiology
- Preventive Medicine
- Public Health
Background:
- Chronic heart failure (HF) prevalence is epidemic, necessitating a focus on prevention.
- New US guidelines classify HF into four stages, from at-risk to refractory.
- Coronary artery disease and hypertension are major contributors to HF development.
Purpose of the Study:
- To review the current understanding of heart failure prevention strategies.
- To identify risk factors and effective interventions for HF prevention.
- To discuss the role of various medications in preventing HF.
Main Methods:
- Literature review of current guidelines and clinical trial data.
- Analysis of risk factors including hypertension, left ventricular hypertrophy, and diabetes.
- Evaluation of pharmacological interventions such as ACE inhibitors, beta-blockers, and diuretics.
Main Results:
- Hypertension and left ventricular hypertrophy are significant independent risk factors for HF.
- ACE inhibitors and beta-blockers demonstrate benefits in patients with overt HF and may aid prevention.
- Ramipril has shown potential in preventing HF in at-risk individuals without left ventricular dysfunction.
Conclusions:
- Controlling risk factors like hypertension and hyperlipidemia is vital for HF prevention.
- ACE inhibitors and beta-blockers are recommended for HF prevention due to their established benefits.
- Further research is needed to clarify the role of antiplatelet agents, warfarin, and statins in HF prevention.
Abstract:
The prevalence and incidence of chronic heart failure (HF) have now reached epidemic proportions. However, the issue of the prevention of HF has been raised only recently. New US guidelines have introduced a new classification system that includes 4 categories: patients at risk, patients with asymptomatic left ventricular dysfunction, patients with symptomatic HF, and those with refractory HF. Because coronary artery disease is the major cause of HF, its risk factors are also those of HF. Hypertension favors the development of HF through accelerated atherosclerosis and increased left ventricular wall stress and hypertrophy. Left ventricular hypertrophy is also a powerful risk factor for HF, independent of blood pressure. Angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, and diuretics are the antihypertensive agents that have been associated with favorable effects in patients with overt HF. Therefore, they may be preferred in the prevention of this syndrome. Diabetes is the most frequent noncardiac comorbidity of HF and is independently associated with an increased risk. Normalization of glycemic and glycosylated hemoglobin levels is a desirable goal of treatment. However, no direct evidence exists in the prevention of HF. A greater control of the other risk factors (eg, hypertension, hyperlipidemia) is, on the other hand, particularly important. Beta-blockers and ACE inhibitors have both been shown to have favorable effects across all spectrums of severity of HF. The ACE inhibitor ramipril has also been shown to prevent the development of HF in patients at risk without left ventricular dysfunction. The role of antiplatelet agents, warfarin, and statins is clear in the prevention of the coronary artery disease. However, it has not been adequately assessed in patients with HF and awaits the results of ongoing trials.